MicuRx Pharmaceuticals
3:30 PM - 3:45 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
MicuRx was founded by Dr. Zhengyu Yuan and Dr. Mikhail F. Gordeev, and is led by an experienced, international scientific and management teams. MicuRx has established R&D centers in China and the US, which has capabilities of basic research, drug development, clinical development and registration. We commercialize our own products in China. Historically MicuRx focused on anti-infectives and are now expanding to other therapy areas.
MicuRx has built a robust pipeline of 4 independently developed innovative drug candidates, focusing on new antibiotics against multidrug-resistant “super-bacteria”. Our goal is to license those to a partner for ex-China regions.
MicuRx is also wishes to in-license late-stage or approved medicines for commercialization in China and are considering several different therapy areas.
Please contact us for more information.
MicuRx has built a robust pipeline of 4 independently developed innovative drug candidates, focusing on new antibiotics against multidrug-resistant “super-bacteria”. Our goal is to license those to a partner for ex-China regions.
MicuRx is also wishes to in-license late-stage or approved medicines for commercialization in China and are considering several different therapy areas.
Please contact us for more information.
Ticker:
688373
Exchange:
Shanghai Star Exchange
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
contezolid
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
